[Selective elimination of atherogenic lipoproteins using dextran-sulfate cellulose. Experiences in 2 patients with heterozygote familial hypercholesterolemia].
Extracorporeal elimination of atherogenic lipoproteins with dextran-sulfate-cellulose for lowering of plasma cholesterol levels was tested in 2 patients with familial heterozygous hypercholesterolemia (untreated cholesterol values 12.9 +/- 1.5 and 12.5 +/- 1.2 respectively) in a longterm experiment. One patient was treated weekly for a period of 36 weeks and the other at fourteen days' intervals with simultaneous administration of 40 mg/day Simvastatin (synvinolin, MSD) for 8 weeks. The mean reduction in total cholesterol concentration was 41% in the first case and 54% in the second (combination with Simvastatin). The therapy was well tolerated without side effects.
Riesen
W F
WF
Institut für klinisch-experimentelle Forschung der Universität, Tiefenauspital Universität, Bern.
Descoeudres
C
C
Mordasini
R
R
Girod
M A
MA
D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002482:Cellulose; D003131:Combined Modality Therapy; D016264:Dextran Sulfate; D003911:Dextrans; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008148:Lovastatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D010956:Plasmapheresis / Q000379:methods*; D019821:Simvastatin
D000924:Anticholesteremic Agents; D003911:Dextrans; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D002482:Cellulose; D016264:Dextran Sulfate; D008148:Lovastatin; D019821:Simvastatin
Selektive Elimination atherogener Lipoproteine mit Dextransulfat-Cellulose. Erfahrungen bei 2 Patienten mit heterozygoter, familiärer Hypercholesterinämie.